None listed
Conditions
Interventions
Drug : (1) Selecting and randomly assigning targets
1 Obtain and screen consent form among patients who are scheduled to perform coronary artery contrast or percutaneous coronary artery intervention t
judgme
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 a patient over the age of nineteen 2 Those who fully understand the risks and benefits of participating in the study and who have prior consent; 3 Unstable angina patient 4 Patients who are scheduled or have already received percutaneous coronary artery intervention due to coronary complex lesions ? Coronary artery complex lesions are defined as those that are accompanied by one or more of the following nine. 1) Medina branch lesions (1,1/1,1,0,1,1) with lateral branch sizes greater than 2.5 mm 2) Target vessels are chronic complete pulmonary lesions (=3 months) 3) If it is an unprotected left-wedge lesion (the left-wedge basin lesion also includes a non-vigilant basin lesion).) 4) The inserted stent is a long lesion with a length of 38mm or more. 5) If a coronary artery intervention is performed in two or more major coronary arteries at a time due to a multivascular disease. 6) If multiple stents are required (£3 more stent per patient) 7) In case of coronary stent re-stenosis lesion 8) Serious coronary calcification lesions (encircling calcium in angiography) 9) In case of left - hand, left - hand, and right - hand coronary artery entrance lesions
Exclusion criteria
Exclusion criteria: 1 In case of hemodynamically unstable or psychotropic shock. 2 Serious bleeding (brain bleeding, gastrointestinal bleeding, hematuria, haemostasis, etc.) 3 In the past, there has been a cerebral hemorrhage, a routine ischemia, or a stroke. 4 Sensitive to contrast agents or research drugs (aspirin, prasugrel, clopidogrel) 5 Pregnant or pregnant woman with pregnancy plans during the research period 6 Expected life is less than a year or research protocol cannot be followed due to a shared disease other than the heart; 7 Biomarker positive ACS 8 Patients taking prasugrel or ticagrel with ACS within 1 year 9 If you are older than 75 or weigh less than 60kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| at 1 year Major heart events (death, myocardial infarction, or stent thrombosis) | — |
Secondary
| Measure | Time frame |
|---|---|
| (Any revascularization);All deaths, myocardial infarction, stent thrombosis, sum of all vascular procedures.;bleeding (BARC type 3 or 5);(All-cause death);(Cardiac death);(Myocardial infarction);(Stent thrombosis) (definite or probable);(TLR, target-lesion revascularization);(TVR, target-vessel revascularization);bleeding (BARC type 2, 3 or 5);? NACE (Net adverse clinical events, MACE + BARC type 3 or 5 bleeding) | — |
Countries
Korea, Republic of
Contacts
Public ContactHahn Joo Yong
Samsung Medical Center
Outcome results
None listed